Targeting the Genomic Drivers of Cancer
Kinnate Biopharma is driven by the urgency of cancer patients who need more effective therapies. We utilize our deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, which we refer to as our Kinnate Discovery Engine, to develop targeted therapies.
Our lead programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene, or in the FGFR2 and FGFR3 kinase genes. To help move our programs forward, Kinnate has brought together a management team of precision oncology experts and scientific advisors who publish widely-cited research on topics relevant to the study and treatment of cancer and lead clinical units at experienced precision medicine cancer centers in the United States.
Kinnate Discovery Engine
“Kinnate has assembled an experienced team of precision oncology experts who are focused on the discovery and development of precision medicines for difficult-to-treat genomically defined cancers.”
– Keith T. Flaherty, MD, Kinnate Board and SAB Member
Unmet Need in Targeted Cancer Therapeutics
In the context of cancer treatment, precision medicine represents the genomic sequencing and analysis of patients’ tumors combined with the development and administration of therapies that are designed to target the oncogenic driver to which the cancer is addicted. It has been shown that patients with tumors driven by oncogenic kinases can demonstrate rapid and measurable tumor shrinkage when treated with targeted kinase inhibitor. Furthermore, while therapeutic benefit can often be significant and clinically meaningful, tolerability is frequently improved compared to conventional cancer treatments like chemotherapies.
However, despite the advancement of precision medicine in oncology, there remains a significant unmet need for the majority of cancer patients for whom no genomically targeted therapies exist or for which a resistance to targeted treatments has evolved. It is estimated that only 2% to 3% of patients with advanced or metastatic cancer will have durable responses to currently available targeted therapeutics.
Currently, it is estimated that only 10% of all patients with advanced or metastatic cancer are eligible for targeted therapeutics, in which a defined genomic driver is matched with a currently approved targeted therapy. Of those patients, up to 50% (the responders) will respond to the therapy, while the remainder (the non-responders) gain no clinical benefit due to intrinsic resistance. Furthermore, among the responders, the majority (conservatively estimated at 50% to 80%) will eventually develop acquired resistance, lose their beneficial response to therapy, and experience disease progression despite continued treatment with the targeted therapy.
At Kinnate, we are focused on expanding the reach of targeted oncology therapeutics by developing products that address areas of significant unmet need. Our team fundamentally believes that integrated structure-based drug design, translational research, and collaborative patient-driven precision medicine-based drug development can lead to meaningfully better outcomes for cancer patients.
“There are clear drivers of disease and resistance mutations that will cause current therapies to fail. The Kinnate portfolio addresses these challenges and will potentially contribute meaningful new medicines to patient populations that would benefit from them.”
– Ryan Corcoran, MD, PhD, Kinnate SAB Member